ArticleACS omega2024
Exploring Carbamazepine Polymorph Crystal Growth in Water by Enhanced Sampling Simulations.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Two-Step Nucleation and Amorphization of Carbamazepine Using a Micro-Droplet Precipitation System.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, the polymorphism of the active pharmaceutical ingredient carbamazepine (CBZ) was investigated by using molecular dynamics simulations with an enhanced sampling scheme. A single molecule of CBZ attaching to flat surfaces of different polymorphs was used as a model for secondary nucleation in water. A novel approach was developed to compute the free energy profile characterizing the adsorption of molecules with orientation aligned with the crystal structure of the surface. The distribution of states that showed alignment was used to rescale the adsorption free energy to include only the contribution that is consistent with crystal growth. The resulting free energy surfaces showed favorable thermodynamics for the most stable form, Form III and the second most stable form, Form I. The primary crystallization product, a dihydrate, was found to be less favorable, implying a nonclassical crystallization pathway. We suggest that a major contribution determining the energetics is the hydrophobicity of the surface. This thermodynamic ranking provides valuable information about the molecular pathways of polymorph growth and will further contribute to the understanding of the crystallization process of CBZ, which is imperative since polymorph formation can alter the physical properties of a drug significantly.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.